Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
LANXESS to strengthen its Indian production sites - The Pharma Times | Pharma & Health Care News Portal
Archives

LANXESS to strengthen its Indian production sites

  • Investment of around INR 1250 crores in the next five years
  • Sales in India more than doubled in the last ten years
  • 2018: Successful business year

Mumbai, November 16, 2018: Specialty chemicals company LANXESS is strengthening its asset base in India. The company plans to invest up to INR 1250 crores till 2023. Focus areas of the investment will be the businesses for chemical intermediates, high-performance plastics and water treatment products. LANXESS had already invested a sizeable amount in India over the years, among others for greenfield investments and acquisitions. The company currently operates production facilities for five business units at its sites in Jhagadia and Nagda.

“The Indian economy is currently the world’s fastest rising major economy, with the chemical industry as one of the fastest growing sectors. We aim to even better capitalize the huge potential of the Indian chemical market and are therefore now launching a major investment package,” said Hubert Fink, Member of the Board of Management of LANXESS AG.

Since it has been incorporated into India in 2004, LANXESS has steadily grown its business in terms of asset base and turnover. In the last ten years, sales in India have more than doubled from INR 1008 crores to INR 2608 crores. 2018 has also been a good year so far for LANXESS India. Turnover increased by 14 percent in the first nine months compared to the same period last year.

The main growth driver for LANXESS in India is the changing population which is rapidly becoming larger, younger, more middle class and more urban.

“The demographic trend in India is leading to an increased demand in the areas of mobility, urbanization, nutrition and clean water.

LANXESS can cater these demands with its wide portfolio of specialty chemicals,” said Neelanjan Banerjee, Managing Director and Country Speaker of LANXESS in India.

Among the products supplied by LANXESS are high-performance plastics for the automotive and electronics industries, flame retardants for application in the automotive and construction industries, chemical intermediates and active ingredients for the use in agriculture as well as ion exchange resins and reverse osmosis membranes for the processing and cleaning of water.

LANXESS in India

In India, LANXESS is represented through all its ten business units, operating out of its registered office in Thane and sales offices in New Delhi and Chennai with around 900 employees across its operations.

LANXESS operates production facilities for its business units Liquid Purification Technologies (ion exchange resins), High Performance Materials (high-performance plastics), Material Protection Products (biocides) and Rhein Chemie (polymer bound rubber chemicals and release agents) in Jhagadia in Gujarat. The business unit Advanced Industrial Intermediates has production facilities both in Jhagadia and Nagda in Madhya Pradesh.

Corporate Comm India(CCI Newswire)

 

The Pharma Times News Bureau

Recent Posts

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

3 days ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

5 days ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

2 weeks ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

2 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

3 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

3 weeks ago